U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry EPIMERIC
Molecular Formula C20H23N7O7
Molecular Weight 473.4393
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEUCOVORIN

SMILES

NC1=NC(=O)C2=C(NCC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1

InChI

InChIKey=VVIAGPKUTFNRDU-ABLWVSNPSA-N
InChI=1S/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/t12?,13-/m0/s1

HIDE SMILES / InChI

Description

Leucovorin is a compound similar to folic acid, which is a necessary vitamin. It has been around and in use for many decades. Leucovorin is a medication frequently used in combination with the chemotherapy drugs fluoruracil and methotrexate. Leucovorin is not a chemotherapy drug itself, however it is used in addition to these chemotherapy drugs to enhance anticancer effects (with fluorouracil) or to help prevent or lessen side effects (with methotrexate). Leucovorin is also used by itself to treat certain anemia problems when folic acid deficiency is present.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
LEUCOVORIN CALCIUM
Palliative
LEUCOVORIN CALCIUM
Palliative
LEUCOVORIN CALCIUM

Cmax

ValueDoseCo-administeredAnalytePopulation
51 μM
500 mg/m² 1 times / 5 weeks other, intravenous
LEUCOVORIN CALCIUM plasma
Homo sapiens
96 μM
500 mg/m² 1 times / week other, intravenous
LEUCOVORIN CALCIUM plasma
Homo sapiens
391 ng/mL
25 mg single, oral
LEUCOVORIN CALCIUM plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
364 mM × min
500 mg/m² 1 times / 5 weeks other, intravenous
LEUCOVORIN CALCIUM plasma
Homo sapiens
71 mM × min
500 mg/m² 1 times / week other, intravenous
LEUCOVORIN CALCIUM plasma
Homo sapiens
1810 mg × h/mL
25 mg single, oral
LEUCOVORIN CALCIUM plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
500 mg/m² 1 times / week other, intravenous
LEUCOVORIN CALCIUM plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer









Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
200 mg/m2 or 20 mg/m2 in Advanced Colorectal Cancer, 10 mg/m2 in Leucovorin Rescue After High-Dose Methotrexate Therapy and up to 1 mg daily in Megaloblastic Anemia Due to Folic Acid Deficiency.
Route of Administration: Intravenous
In Vitro Use Guide
RPMI 1788 cells revealed a high intrinsic resistance to methotrexate (MTX). The cytotoxic effect of high concentrations of MTX (10 -5 M) was reversed by relatively low (10 -6 M) concentrations of simultaneously added leucovorin (LV). The enhancement of cell survival was less marked when LV application was delayed for 12 h.